Treatment come in Rheumatology clinic, Lampang Hospital

Main Article Content

Thawatchai Panthong


There are many patients with arthritic disease who are not diagnosed and treated properly due to the lack of specialists in rheumatology and the change of new treatment modality. The objective is to study the type of the disease, the incidence, and the treatment outcome by Disease Modifying Antirheumatic Drugs (DMARDs) in rheumatic outpatient clinic, Lampang Hospital. A one year retrospective study was done during October 1, 2005 to September 30, 2006. The results demomstrated 270 patients who were diagnosed into following diseases : 109 cases of rheumatoid arthritis, 31 cases of systemic lupus erythematosus (SLE), 4 case of undifferentiated connective tissue disease (UCTD), 24 cases of scleroderma, 1 case of polyarteritis nodosa (PAN), 12 cases of spondyloarthropathy, 23 cases of gout, 16 vases of osteoarthritis, 10 cases of Overlap Syndrome, 10 cases of Polymyositis, 6 cases of Myofacial pain syndrome, 5 cases of Psoriatic Arthritis, 5 cases of L-C spondylosis and 2 cases of Juvenile rheumatiod Arthritis.
Among Rheumatoid Arthritis patients. There were female to more than male (ratio was 3.4 : 1.0 ) and the most common age was found in the range of 41-60 yeas. Most patients had the history of more than 1-year disease and the disease was still active.
After the treatment of DMARDS with the average of 2 drugs, 54.3% of the patients can archive the remission of the disease.
In conclusion, the early diagnosis and proper management give the good treatment outcome and reduce the morbidity of the patients. Hence, the general practices should keep the update of the knowledge and the practical skill in the management of these rheumatic patients. The increased training of the rheumatologic specialists is also mandatory in improving the care of the patients.


Download data is not yet available.

Article Details

How to Cite
Panthong, T. (2022). Treatment come in Rheumatology clinic, Lampang Hospital. Lampang Medical Journal, 28(2), 100–110. Retrieved from
Original Article


Van Aken J, Lard LR, Le Cessie S. Hazes JMW, Breedveld FC. Huizinga. Radiologic outcome after four years of eary versus delayed treatment stategy in patients with recent onset Rheumatoid Arthritis. Ann Rheum Dis 2004;63:274-9.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis 2002 Update. Arthritis Rheum 2002;46:328-46.

O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine,

methotrexate and sulfasalazine, or a combination of the three medication: Resules of a two year,randomized, doble-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.

สุรศักดิ์ นิลกานุวงศ์. โรคข้ออักเสบรูมาตอยด์ ใน: สุรศักดิ์ นิลกานุวงศ์, สุรวุฒิ ปรีชานนท์, บรรณาธิการ. ตำราโรคข้อ. พิมพ์ครั้งที่ 2.

กรุงเทพมหานคร: เอส.พี.เอ็น การพิมพ์; 2547. น. 177-217.

ไพจิตต์ อัศวธนบดี. Rheumatology for the Non-Rheumatologist. กรุงเทพมหานคร: ซิตี้พริ้นท์; 2549.

Kirwan JR. Systematic low dose glucocorticoid treatment in Rheumatoid Arthritis. In: O'Dell, editor. Rheumatic Disease Clinics of North America : Rheumatoid Arthritis Orlando : W.B.Saunders ; 2001. p.389-403.

แนวทางการใช้ Anti-Tumor Neorosis Factor 2 Therapies ในโรครูมาติก. วารสารโรคข้อและรูมาติสซั่ม. 2550;16:56-73.

Lipsky PE, Van der Heijde, St Clair EW, Furst DE, Dreedveld FC, Kalden JR, et al. Infliximap and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.

Cohens S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with analinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate : results of a twenty-four-week multicenter,

randomized, double-blind, placebo-controlled trial. arthritis Rheum 2002;46:614-24.

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficicacy of B-cell-targeted therapy with rituximap in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.